terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

FullPAC, Inc. Issues Spring 2026 Chairman’s Letter

View original at globenewswire.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter Virginia Beach, VA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- FullPAC, Inc. (“FullPAC” or the “Company”) (Nasdaq Reserved: GOTV), a premier nonpartisan campaign technology provider for more than 5,000 U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FullPAC is well positioned to serve the growing political spending market as campaign investment builds ahead of the 2028 Presidential election

    80% confidence
  • Advocacy Lab contributes meaningful recurring revenue and serves as a natural entry point into the broader FullPAC platform, strengthening client retention and expanding long-term revenue opportunities

    80% confidence
  • FullPAC is positioned to become the premier public-market pure play on America's growing political campaign industry

    80% confidence
  • Cash flows from Advocacy Lab will cover its direct purchase consideration by March 31, 2026, several months ahead of schedule

    80% confidence
  • Political campaign spending has surged ever higher since Citizens United was decided in 2010

    80% confidence
  • The 2026 election cycle's projected $10.8 billion advertising spending makes it the most expensive non-presidential election cycle in history, marking a more than 20% increase over 2022 midterms

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com